Dyne Therapeutics Reports One-Year DM1 Trial Data Showing Functional Gains
Phase 1/2 ACHIEVE trial data show Z-Basivarsen improved function in myotonic dystrophy patients at 12 months versus baseline, placebo, and natural history cohort.
Dyne Therapeutics has released additional one-year clinical data from its Phase 1/2 ACHIEVE trial evaluating Z-Basivarsen, also known as DYNE-101, as a potential treatment for Myotonic Dystrophy Type 1, a rare and progressive neuromuscular disease.
Data drawn from a pooled dose group of participants originally enrolled in the multiple ascending dose portion of the trial demonstrated functional improvement at the 12-month mark. Investigators measured outcomes against three separate benchmarks: each participant's own baseline, a placebo control group, and a matched natural history cohort — a comparator drawn from patients who did not receive the experimental therapy.
Read more PwC: Companies Risk Losing Top AI Talent While Others Fall Behind →
The triple-comparison approach strengthens the signal from a relatively small early-stage trial by situating results within the broader trajectory of the disease. Myotonic Dystrophy Type 1 is a progressive condition, meaning untreated patients typically decline over time, making improvement against a natural history cohort a particularly meaningful data point for assessing therapeutic effect.
The ACHIEVE findings represent an early but closely watched milestone for Dyne as the company advances its RNA-targeting platform. Z-Basivarsen is designed to address the underlying genetic mechanism of DM1, and one-year data from a Phase 1/2 study are considered a key inflection point for informing the design of later-stage trials.
Continue reading at GlobeNewswire - Industry News on Financial Services.
